Sanara MedTech Earnings Call Signals Growth Momentum

Sanara MedTech ((SMTI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sanara MedTech’s latest earnings call struck an optimistic tone, with management emphasizing record revenue, margin expansion, and a swing to positive operating cash flow in 2025. While executives acknowledged higher leverage, a Q4 net loss, and THP wind‑down costs, they framed these as strategic trade‑offs to fund growth, backing up confidence with specific 2026 guidance.

Record Revenue Clears $100 Million Milestone

Sanara MedTech reported full‑year 2025 net revenue of $103.1 million, the first time the company has crossed the $100 million mark. That figure represents 19% year‑over‑year growth, underscoring accelerating demand for its advanced wound and surgical products despite pockets of operating pressure.

Margins Widen As Profitability Metrics Improve

The company’s gross margin expanded by roughly 200 basis points to 93%, supporting a sharp improvement in profitability. Adjusted EBITDA rose 86% to $17.0 million, while the net loss from continuing operations narrowed by about $1.5 million, an estimated 80% year‑over‑year reduction.

Operating Cash Flow Swings Sharply Positive

Sanara generated $6.8 million in cash from operating activities in 2025, a notable shift from $24,000 of cash used in operations the prior year. Management noted this figure includes THP‑related outflows, suggesting the core continuing business is generating even stronger underlying cash.

Q4 Revenue Holds Up Despite Storm‑Boosted Compare

Fourth‑quarter 2025 net revenue came in at $27.5 million, up 5% from the prior year. Excluding roughly $1.8 million of storm‑driven BIASURGE sales that inflated Q4 2024, Sanara’s Q4 2025 revenue rose about 13% year‑over‑year and landed at the high end of management’s prior guidance range.

Distributor Network And Facility Reach Expand

Commercial reach widened as the contracted distributor base increased to more than 450, up from over 350 at the end of 2024, roughly a 29% jump. Sanara’s products were sold into more than 1,450 health care facilities by year‑end, compared with over 1,300 a year earlier, with contractual access across more than 4,000 facilities.

Vizient Contract Marks A Major Channel Win

BIASURGE secured a coveted Innovative Technology contract with group purchasing giant Vizient, effective January 1, 2026. The deal opens access to about 1,800 Vizient facilities at contracted pricing, significantly expanding Sanara’s addressable account base for one of its key antimicrobial surgical offerings.

Clinical Data, IP And Pipeline Strengthen

Management highlighted new clinical support, noting BIASURGE showed strong antimicrobial efficacy with low cytotoxicity, while ALLOCYTE Plus delivered encouraging fusion outcomes over 24–36 months. The company advanced its intellectual property, converting 11 provisional patents to nonprovisional, filing U.S. and PCT protections, and keeping OsStic on track for U.S. launch in Q1 2027.

Guidance Underscores Confidence And Transparency

Sanara reaffirmed 2026 net revenue guidance of $116.0–$121.0 million, implying about 13–17% growth over 2025, and projected Q1 2026 revenue of roughly $26.7–$27.2 million. Management said it is comfortable with liquidity, expects operating cash flow to fund sales‑force and R&D investments, and noted the THP wind‑down is largely complete with no material future cash drag.

Q4 Profitability Pressured By Net Loss

Despite top‑line growth, the company posted a Q4 2025 net loss from continuing operations of $1.1 million, or $0.13 per diluted share, reversing a $0.9 million profit a year earlier. Reported operating income for the quarter fell to $1.1 million from $2.3 million, reflecting higher costs and strategic spend.

Noncash Impairment And Higher OpEx Weigh On Results

Operating expenses rose 13% in Q4 to $24.6 million, partially driven by a $1.8 million noncash impairment linked to IP write‑downs. R&D spending also climbed by $1.2 million, which management framed as necessary investment to advance its innovation pipeline and sustain future growth.

Debt Load Rises Alongside Interest Expense

Long‑term debt increased to $46.0 million at year‑end 2025, up from $30.7 million a year earlier, a roughly 50% jump that boosted financial leverage. The heavier debt burden contributed to higher other expense in Q4, mainly interest and fees on the CRG term loan, as well as a larger share of losses from equity method investments.

THP Wind‑Down Masks Stronger Core Cash Generation

The wind‑down of THP consumed $5.3 million of cash in the second half of 2025, less than prior midpoint expectations but still a notable drag. Management estimates around $9 million of THP‑related cash use is embedded in the reported $6.8 million operating cash inflow, implying the continuing operations produced significantly more cash than the headline figure suggests.

Under‑Penetrated Surgeon Base Remains Key Upside

While Sanara’s products are contracted in more than 1,450 facilities and accessible in over 4,000, surgeon usage within these institutions remains relatively low. That under‑penetration underscores both a reliance on future adoption to drive growth and a sizable runway if physician engagement and procedure‑level usage can be scaled.

Vizient Ramp Carries Execution And Timing Risk

Management cautioned that the Vizient contract will not instantly translate into large revenue contributions in 2026, given the need for facility‑level education and onboarding. Investors should expect a gradual adoption curve as hospitals and surgeons become familiar with BIASURGE, making execution in the field crucial to unlocking the contract’s full value.

Sanara MedTech’s earnings call painted a picture of a company transitioning from proof‑of‑concept to scaled commercialization, with record revenue and improved cash generation balancing near‑term profit volatility and leverage. The story now hinges on execution: converting expanded access and strong clinical data into deeper surgeon adoption while managing debt and investment pace carefully.